BusinessFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell TransplantationBy Nasdaq OMXSep 26, 2016, 12:00 PM UTC
BusinessCancer Genetics, Inc. and ApoCell Announce Partnership Focused on Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform for Rare Cell Capture and DetectionBy Nasdaq OMXSep 26, 2016, 11:31 AM UTC
BusinessMD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple CancersBy Nasdaq OMXSep 26, 2016, 11:30 AM UTC
BusinessMyriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel TestingBy Nasdaq OMXSep 26, 2016, 11:05 AM UTC
BusinessAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCVBy Nasdaq OMXSep 23, 2016, 3:50 PM UTC
BusinessApricus Biosciences Announces $4.6 Million Registered Direct OfferingBy Nasdaq OMXSep 23, 2016, 12:00 PM UTC
BusinessMacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology RoundtableBy Nasdaq OMXSep 23, 2016, 11:30 AM UTC
BusinesspSivida to Present at the Ladenburg Thalmann Annual Healthcare ConferenceBy Nasdaq OMXSep 22, 2016, 1:01 PM UTC
